Zydus’ Third Quarter Results Met With Mixed Analyst Reactions

As Firm Strikes Fresh Deal With Synthon For 505(b)(2) Product

Zydus’ latest results faced scrutiny from industry analysts due to a mixed performance where weaker revenue in the Indian company’s domestic market was offset by growth in the US. Meanwhile, the firm has just agreed a deal with Synthon for a 505(b)(2) hybrid product in the US.

Zydus lifesciences building, India
Zydus Lifesciences has announced new North American leadership • Source: Shutterstock

More from Earnings

More from Generics Bulletin